FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1 - Fashoyin‐Aje, Lola; Donoghue, Martha; Chen, Huanyu; He, Kun; Veeraraghavan, Janaki; Goldberg, Kirsten B; Keegan, Patricia; McKee, Amy E; Pazdur, Richard (The oncologist (Dayton, Ohio), 2019)
Keywords: Accelerated approval; Adenocarcinoma - drug therapy; Adenocarcinoma - pathology; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized - pharmacology; Antibodies, Monoclonal, Humanized - therapeutic use; B7-H1 Antigen - metabolism; Esophageal Neoplasms - drug therapy; Esophageal Neoplasms - pathology; Esophagogastric Junction - pathology; Female; GEJ adenocarcinoma; Humans; Male; PD‐L1; Regulatory Issues: FDA; Stomach Neoplasms - drug therapy; Stomach Neoplasms - pathology; United States; United States Food and Drug Administration; Young Adult; United States; Accelerated approval; GEJ adenocarcinoma; PD‐L1